Tagged with STrategy

India As a young pathbreaking transformer in the Indian pharmaceutical landscape, Yogesh Agrawal, managing director of Ajanta Pharma Ltd., shares his desire to accelerate the company’s expansion in the US. Out of the total revenues of USD 308 million for FY17, the USA accounted for 28 million. He talks about the…

Bulgaria Ekaterina Karpuzova, country commercial lead pharmaceuticals at Bayer Bulgaria, explains how the national healthcare system has evolved over the last few years as well as demonstrates the commitment of Bayer Bulgaria to supporting the impact and quality of its solutions through value-based evidence. After starting in Bayer Bulgaria, you went…

Tunisia Fatma Thabet Chiboub, CEO of the Bizerta Economic Activities Park (PAEB) in Tunisia, explains the advantages for a company of establishing itself in the PAEB, the importance of high added-value economic activities for Tunisia, and the central role of the PAEB in stopping the country’s brain drain. Could you tell…

Austria Peter Wimmer, country manager of Angelini Austria and Germany, discusses the tailored long-term strategy that this exciting Italian pharmaceutical company is implementing to establish a boutique portfolio and the importance of scientific data in constructing positive relationships throughout the healthcare community. Furthermore, he highlights the reasons Austria is being addressed…

Canada Wendy Adams, general manager of Galderma Canada, outlines the main achievements of the affiliate since 2013, the best practices she can share with Galderma globally when it comes to managing the company’s three business segments, the strong relationships with dermatologists and other healthcare practitioners she has built, and the significance…

India Sanjay Bhutani, managing director of Bausch & Lomb India and SAARC operations, gives his insights into the thriving visual care industry which has allowed the company to launch 31 intraocular lenses (IOLs) in the last three years and the Good and Services Tax (GST) which presents somewhat of a barrier…

Brazil Alexandre França, CEO of Aspen Pharma Brazil, describes the transformation of the Brazilian organization over the past year, which allowed Aspen Brazil to establish itself as the best performing affiliate of the group despite the country’s economic and political turmoil. Last year, Aspen Brazil was recognized as the group’s best…

Canada Mark Lachovsky, founder and president of Accel Pharma, a Canadian generics company with a unique business model, discusses the inspiring story of how he started and grew the company through challenging times, the important role Accel plays in providing affordable generics drugs to the Canadian population, and his international partnership…

Switzerland In an exclusive interview, Jean-Paul Clozel, former head of Actelion and now CEO of exciting biotech newcomer Idorsia, discusses his new company’s unique drug discovery methodology, the pressure of past success, and how he hopes to usher in a new era of collaboration to tackle disease.   In August 2016,…

Brazil Luciano Finardi, general manager of Celgene Brazil, describes the unrivalled commitment of the company to Brazilian patients and documents the remarkable dedication of Celgene to registering its flagship product in Brazil, as well as the company’s willingness to cope with the country’s unpredictability while establishing its operation in Brazil. Celgene…

Brazil Mauro Loch, general manager of Amgen Brazil, documents the eye-catching turnaround of the affiliate since the beginning of his tenure and provides insights into the company’s unique positioning in Brazil, the outstanding performance of recently launched products, as well as his main priorities to further increase access to Amgen’s life-changing…

Tunisia Walid Chriaa, CEO of SIPHAT, explains the history of the public company’s position in Tunisia, as the pearl of the Tunisian pharmaceutical industry. He also points out a few of the strategies in place to counter the financial struggles that SIPHAT has been under, such as reforms with a 2030…